EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Minocycline and bone marrow–derived mononuclear cells as potential therapeutics for hereditary retinal degenerations

Alba Videla-Ristol, Ana Martínez-Vacas, David García-Bernal iD, Manuel Vidal-Sanz iD, María Paz Villegas-Pérez iD, Diego García-Ayuso iD, Johnny Di Pierdomenico iD

Acta Ophthalmologica · 2026-09 · 104 (6)

DOI: 10.1111/aos.70108 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Ophthalmologica, online erschienen am 10.03.2026. Verfasst von Alba Videla-Ristol und 6 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Oftalmología, Facultad de Medicina, Universidad de Murcia, Murcia, Spain. Hauptthemen laut MEDLINE: Minocycline, Retinal Degeneration, Bone Marrow Transplantation. Die Arbeit nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Instituto de Salud Carlos III, MCIN/AEI, NextGenerationEU.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To assess in Royal College of Surgeons ( RCS ) rats if the combination of two previously documented neuroprotective strategies: minocycline administration and bone marrow–derived mononuclear cells ( BM ‐ MNCs ) intravitreal transplantation, offers enhanced neuroprotection compared with each treatment alone.

Methods

Forty‐eight homozygous pigmented RCS rats were divided into four groups: control, intravitreal BM‐MNC transplantation, systemic minocycline treatment or combined therapy. Treatments were administered at postnatal day (P) 27–28. Animals were evaluated in vivo by spectral domain optical coherence tomography (SD‐OCT) at P28, P35 and P51. Retinal sections were analysed for photoreceptor survival (outer nuclear layer [ONL] cell counts), synaptic preservation (Bassoon immunoreactivity), microglial activation (Iba‐1+ cells) and macroglial reactivity (glial fibrillary acidic protein [GFAP] expression).

Results

Both BM‐MNC and minocycline monotherapies significantly preserved total and outer retinal thicknesses and increased ONL nuclei counts compared with controls. Combined treatment yielded superior protection at both P35 and P51. Minocycline alone or in combination significantly reduced microglial cell activation, while BM‐MNCs alone or in combination significantly reduced GFAP expression. Synaptic integrity in the outer plexiform layer, assessed via Bassoon labelling, was significantly better preserved in treated animals, with the highest levels observed in the combined therapy group.

Conclusions

Minocycline and BM‐MNCs provide complementary neuroprotective effects in the RCS rat model. While minocycline reduces microglial activation, BM‐MNCs modulate macroglial response. Their combination enhances photoreceptor survival and synaptic preservation more effectively than either treatment alone. These findings support the therapeutic potential of combining pharmacological and cell‐based interventions in hereditary retinal degenerations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MinocyclineRetinal DegenerationBone Marrow TransplantationAnimalsRatsDisease Models, AnimalTomography, Optical CoherenceIntravitreal InjectionsRats, Mutant StrainsAnti-Bacterial Agents

Stichwörter der Autor:innen

RCS ratbone marrow–derived mononuclear cellsglial activationminocyclinephotoreceptor neuroprotectionretinal degeneration

Substanzen

MinocyclineAnti-Bacterial Agents

Autor:innen und Institutionen

  • Departamento de Oftalmología, Facultad de Medicina, Universidad de Murcia, Murcia, Spain.
  • Instituto Murciano de Investigación Biosanitaria-Virgen de la Arrixaca Pascual Parrilla (IMIB-Arrixaca), Murcia, Spain.
  • Departamento de Bioquímica, Biología Molecular B e Inmunología, Facultad de Medicina, Universidad de Murcia, Murcia, Spain.

ORCID-Profile: David García-Bernal, Manuel Vidal-Sanz, María Paz Villegas-Pérez, Diego García-Ayuso, Johnny Di Pierdomenico

Förderung

  • Instituto de Salud Carlos III
  • MCIN/AEI
  • NextGenerationEU
  • FUNDACION SÉNECA - AGENCIA DE CIENCIA Y TECNOLOGÍA DE LA REGIÓN DE MURCIA - GERM (Ayudas a Grupos de Investigación de Excelencia de la Región de Murcia)

Zitieren

APA

Videla-Ristol, A., Martínez-Vacas, A., García-Bernal, D., Vidal-Sanz, M., Villegas-Pérez, M. P., García-Ayuso, D., & Di Pierdomenico, J. (2026). Minocycline and bone marrow–derived mononuclear cells as potential therapeutics for hereditary retinal degenerations. Acta Ophthalmologica, 104(6). https://doi.org/10.1111/aos.70108

Vancouver

Videla-Ristol A, Martínez-Vacas A, García-Bernal D, Vidal-Sanz M, Villegas-Pérez MP, García-Ayuso D, et al. Minocycline and bone marrow–derived mononuclear cells as potential therapeutics for hereditary retinal degenerations. Acta Ophthalmologica. 2026;104(6). doi:10.1111/aos.70108

BibTeX
@article{VidelaRistol2026,
  author = {Videla-Ristol, Alba and Martínez-Vacas, Ana and García-Bernal, David and Vidal-Sanz, Manuel and Villegas-Pérez, María Paz and García-Ayuso, Diego and Di Pierdomenico, Johnny},
  title = {Minocycline and bone marrow–derived mononuclear cells as potential therapeutics for hereditary retinal degenerations},
  journal = {Acta Ophthalmologica},
  year = {2026},
  volume = {104},
  number = {6},
  doi = {10.1111/aos.70108}
}
Kostenlos starten →